Phase 3 Clinical Trials With Primary Completion Dates in January 2023

This is a list of Phase 3 trials with primary completion dates in January 2023 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

Symbol Company Primary Completion Date Phase NCT ID Title
ACAD ACADIA Pharmaceuticals Inc. 2023-01-01 Phase 3 NCT04776746 Open-Label Extension Study of Trofinetide for Rett Syndrome
ACHV Achieve Life Sciences, Inc. 2023-01-01 Phase 3 NCT05206370 A Second Study of Cytisinicline for Smoking Cessation in Adult Smokers
BHVN Biohaven Ltd. 2023-01-01 Phase 3 NCT04649242 Randomized Study in Children and Adolescents With Migraine: Acute Treatment
CLVSQ Clovis Oncology, Inc. 2023-01-01 Phase 3 NCT04227522 Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients
CYDY CytoDyn Inc. 2023-01-01 Phase 3 NCT04901676 Leronlimab in Moderately Ill Patients With COVID-19 Pneumonia
IVBXF Innovent Biologics, Inc. 2023-01-01 Phase 3 NCT03700476 Sintilimab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma
NEPH Nephros, Inc. 2023-01-01 Phase 3 NCT03769441 Effect of Ferric Carboxymaltose on Exercise Capacity After Kidney Transplantation
STMH Stem Holdings, Inc. 2023-01-01 Phase 3 NCT05004324 Safety and Efficacy of FURESTEM-AD Inj. for Moderate to Severe Atopic Dermatitis (AD)